Li X, Cui H, Sandstedt B, Nordlinder H, Larsson E, Ekström T J
Department of Clinical Neuroscience, Experimental Alcohol and Drug Addiction Research Section, Karolinska Hospital, Stockholm, Sweden.
J Endocrinol. 1996 Apr;149(1):117-24. doi: 10.1677/joe.0.1490117.
We have studied the insulin-like growth factor-II gene (IGF2) promoter usage in normal human liver from fetal to late adult life by quantifying the specific transcripts by RNase protection assays using exon-specific probes. While the fetal liver uses only three promoters (P2, P3, P4) for the transcription of IGF2, all four promoters can be used from the age of 2 months after birth. The levels of the individual promoter transcripts vary substantially during development and the P3 promoter, which is a highly active fetal promoter, was not used by all the investigated adult patients but was detected in 30% of the adult group as a whole. The P1 promoter, which has previously been considered as the only one responsible for IGF2 transcription in the postnatal/adult liver, displayed a trend of increasing relative and absolute activity throughout life, but in some adult cases it was found to be less active than the P4 promoter. The P4 promoter displayed an age-related trend of decreasing activity from a very high fetal level, but individual exceptions were apparent. The P2 promoter transcript, peaking at the age of 2 months, showed a relatively even absolute amount from 18 months onwards. Thus, while P2 and P3 were both found to reach their highest activity after birth, the P4 promoter displayed its highest transcription at the fetal stage. The total IGF2 transcription, primarily from P2, P3 and P4, was found to peak shortly after birth. After this age, the P3 promoter transcript declined most rapidly and a low or zero amount was detected in adulthood. From the age of 18 months to old adulthood the total IGF2 mRNA, derived primarily from P1, P2 and P4, displayed a relatively even amount (approximately one tenth) of that seen at the peak at 2 months. This data may be important in relation to translatability of the various IGF2 transcripts.
我们通过使用外显子特异性探针的核糖核酸酶保护试验对特定转录本进行定量,研究了从胎儿期到成年后期正常人类肝脏中胰岛素样生长因子-II基因(IGF2)启动子的使用情况。虽然胎儿肝脏仅使用三个启动子(P2、P3、P4)来转录IGF2,但出生后2个月起所有四个启动子均可被使用。各个启动子转录本的水平在发育过程中差异很大,P3启动子是一个高度活跃的胎儿启动子,并非所有接受调查的成年患者都使用它,但在整个成年组中有30%检测到该启动子。P1启动子先前被认为是出生后/成年肝脏中唯一负责IGF2转录的启动子,其相对活性和绝对活性在整个生命过程中呈上升趋势,但在一些成年病例中发现其活性低于P4启动子。P4启动子显示出与年龄相关的活性下降趋势,从胎儿期的非常高水平开始,但个别例外情况明显。P2启动子转录本在2个月龄时达到峰值,从18个月起其绝对量相对均匀。因此,虽然发现P2和P3在出生后均达到最高活性,但P4启动子在胎儿期表现出最高转录水平。发现主要来自P2、P3和P4的总IGF2转录在出生后不久达到峰值。在这个年龄之后,P3启动子转录本下降最快,成年期检测到的量很低或为零。从18个月龄到成年后期,主要来自P1、P2和P4的总IGF2 mRNA呈现出相对均匀的量(约为2个月龄时峰值的十分之一)。这些数据对于各种IGF2转录本的可翻译性可能很重要。